
Chondroitin Sulfate
Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. Chondroitin sulfate is composed of alternating 1,3-N-acetyl-β-d-galactosamine and 1,4-β-d-glucuronic acid units which bear 4-O- and/or 6-O-sulfations at the N-acetylgalactosamine units disposed of in specific patterns. Depending on the predominating disaccharide unit, it will present different biological activities. Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe. — DrugBank
- IUPAC name
- (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
- Molecular formula
- C13H21NO15S
- Molecular weight
- 463.37 g/mol
- Exact mass
- 463.06319014 Da
- XLogP3
- -4.8
- Topological polar surface area
- 267.0 Ų
- Hydrogen-bond donors
- 8
- Hydrogen-bond acceptors
- 15
- Covalent units
- 1
- Defined stereocentres
- 10
Also known as
16 more reported names
External database identifiers
- ChEMBL:CHEMBL5266347
- EPA DTXSID:DTXSID601017238
- PubMed:5601
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.